Investors are "piling into" GSK due to several key shifts in the company's fundamentals:
GSK remains a staple for income-seeking investors, with management showing a commitment to increasing payouts: buy gsk shares
: 2025 revenue hit £32.7bn (up 7%), driven by high-margin specialty medicines like HIV and Respiratory treatments. Investors are "piling into" GSK due to several
Are you considering GSK primarily for its or for long-term growth in its oncology pipeline? buy gsk shares